Kenneth W. Narducy
President at St. Charles Pharmaceuticals
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Judith Kelleher-Andersson | M | - |
NeuroNascent, Inc.
 NeuroNascent, Inc. Pharmaceuticals: MajorHealth Technology NeuroNascent, Inc. is an IND-enabling stage biopharmaceutical company that develops orally available, novel therapeutics aimed at halting or reversing chronic neurological disorders. It offers disease-modifying therapeutics for some of the most difficult to treat brain disorders that include Alzheimer's disease, Parkinson's disease, and Down syndrome. The Company is founded by Judith Kelleher-Andersson in May 2004 and is headquartered in Clarksville, MD. | 20 years |
| John Koerner | M | 81 |
St. Charles Pharmaceuticals
| - |
| Kathleen L. Mattis | F | - |
NeuroNascent, Inc.
NeuroNascent, Inc. Pharmaceuticals: MajorHealth Technology NeuroNascent, Inc. is an IND-enabling stage biopharmaceutical company that develops orally available, novel therapeutics aimed at halting or reversing chronic neurological disorders. It offers disease-modifying therapeutics for some of the most difficult to treat brain disorders that include Alzheimer's disease, Parkinson's disease, and Down syndrome. The Company is founded by Judith Kelleher-Andersson in May 2004 and is headquartered in Clarksville, MD. | 20 years |
| Robin Oegerle | F | - |
NeuroNascent, Inc.
NeuroNascent, Inc. Pharmaceuticals: MajorHealth Technology NeuroNascent, Inc. is an IND-enabling stage biopharmaceutical company that develops orally available, novel therapeutics aimed at halting or reversing chronic neurological disorders. It offers disease-modifying therapeutics for some of the most difficult to treat brain disorders that include Alzheimer's disease, Parkinson's disease, and Down syndrome. The Company is founded by Judith Kelleher-Andersson in May 2004 and is headquartered in Clarksville, MD. | - |
| Maurice Gagnon | M | - |
NeuroNascent, Inc.
NeuroNascent, Inc. Pharmaceuticals: MajorHealth Technology NeuroNascent, Inc. is an IND-enabling stage biopharmaceutical company that develops orally available, novel therapeutics aimed at halting or reversing chronic neurological disorders. It offers disease-modifying therapeutics for some of the most difficult to treat brain disorders that include Alzheimer's disease, Parkinson's disease, and Down syndrome. The Company is founded by Judith Kelleher-Andersson in May 2004 and is headquartered in Clarksville, MD. | - |
| Emer Leahy | M | 58 |
NeuroNascent, Inc.
NeuroNascent, Inc. Pharmaceuticals: MajorHealth Technology NeuroNascent, Inc. is an IND-enabling stage biopharmaceutical company that develops orally available, novel therapeutics aimed at halting or reversing chronic neurological disorders. It offers disease-modifying therapeutics for some of the most difficult to treat brain disorders that include Alzheimer's disease, Parkinson's disease, and Down syndrome. The Company is founded by Judith Kelleher-Andersson in May 2004 and is headquartered in Clarksville, MD. | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Aleksandrs Zhavoronkov | M | - |
Colby Pharmaceutical Co.
 Colby Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Colby is transitioning to a clinical stage drug development company. The company was launched as a Wisconsin Alumni Research Foundation (WARF) spin-out and is strategically aligned with leading clinicians and drug discovery scientists at the University of Wisconsin Paul P. Carbone Comprehensive Cancer Center (UWCCC). Colby is accessing data from funded grants and private investment to develop its therapeutic drugs for therapy-resistant and hypoxic conditions. Colby's lead drugs have unique mechanisms of action and target specific pathways. The company is focused on clinical development of its lead drugs, CPC-100 and -200, in patients with recurrent PCa and other solid tumors, respectively. In 2010, Colby plans to launch a Phase I/IIa study of CPC-100 in men with PCa who fail Androgen Depletion Therapy, as evidenced by rising PSA levels. CPC-200 is being scheduled for a Phase I/IIa in men with high-risk tumors. Colby's two pipeline drugs, CPC-300 and CPC-410 for therapy-resistant metastatic and hypoxic tumors are in late pre-clinical development and are funded by federal grants, including an awarded Colby SBIR grant and by private investors. The Company has demonstrated safety of its lead drugs following efficacy studies in rodents and toxicology studies in mice, rats, and dogs. | 1 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 7 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Kenneth W. Narducy
- Personal Network
